

October 21, 2022

News Release

Company: Olympus Corporation  
Yasuo Takeuchi, Director, Representative Executive Officer, President and CEO  
(Code: 7733, Prime, Tokyo Stock Exchange)  
Contact: Takaaki Sakurai, Vice President, Investor Relations  
TEL: +81-3-3340-2111

### **Notice Concerning Changes of Representative Executive Officer and Management Team**

Olympus Corporation ("Olympus") hereby announces that the Board of Directors held today has tentatively decided to change the Olympus's representative executive officer, and the management team as described below. It is scheduled to be decided formally in the Board of Directors at the end of March 2023.

1. Reason for change

Since the announcement of the corporate transformation plan "Transform Olympus" and corporate strategy in 2019, Olympus has been implementing various initiatives, including concentration of its management resources in medical field, active investment in growth areas, and structural reform of fixed costs. These efforts have resulted in improvement of efficiency and profitability, strengthening of research and development, and expansion of contributions to customers. Effective on April 1, 2023, we have decided to change the representative executive officer and management team for shifting to the next level of growth in FY2024 and beyond with further improving organizational efficiency.

2. Names and job titles of newly appointed executive officers

(1) Newly appointed representative executive officers

Name	Current job titles	New job titles after April 1, 2023
Yasuo Takeuchi	Director, Representative Executive Officer, President and Chief Executive Officer	Director, Representative Executive Officer, and Executive Chairman and ESG Officer
Stefan Kaufmann	Director, Executive Officer, Chief Administrative Officer (CAO), Chief Strategy Officer (CSO) and ESG Officer	Director, Representative Executive Officer, President and Chief Executive Officer

(2) Newly appointed executive officers

Name	Current job titles	New job titles after April 1, 2023
Frank Drewalowski	Corporate Officer and Endoscopic Solutions Division Head	Executive Officer and Endoscopic Solutions Division Head
Gabriela Kaynor	Corporate Officer and Therapeutic Solutions Division Head	Executive Officer and Therapeutic Solutions Division Head
Shigeto Ohtsuki	Corporate Officer and Human Resources Head	Executive Officer and Chief Human Resources Officer
Pierre Boisier	Corporate Officer and Chief Quality Officer	Executive Officer and Chief Quality Officer

Note: André Roggan will remain as Executive Officer and Chief Technology Officer, Tetsuo Kobayashi will remain as Executive Officer and Chief Manufacturing and Supply Officer, Chikashi Takeda will remain as Executive Officer and Chief Financial Officer, and Nacho Abia will remain as Executive Officer and take the role of Chief Strategy Officer.

3. New management team from April 1, 2023

Yasuo Takeuchi	Director, Representative Executive Officer, and Executive Chairman and ESG Officer
Stefan Kaufmann	Director, Representative Executive Officer, President and Chief Executive Officer
Frank Drewalowski	Executive Officer and Endoscopic Solutions Division Head
Gabriela Kaynor	Executive Officer and Therapeutic Solutions Division Head
Chikashi Takeda	Executive Officer and Chief Financial Officer
Nacho Abia	Executive Officer and Chief Strategy Officer
Tetsuo Kobayashi	Executive Officer and Chief Manufacturing and Supply Officer
André Roggan	Executive Officer and Chief Technology Officer
Shigeto Ohtsuki	Executive Officer and Chief Human Resources Officer
Pierre Boisier	Executive Officer and Chief Quality Officer

4. Career summary of newly appointed representative executive officer and executive officers

(1) Newly appointed representative executive officer

Stefan Kaufmann

Date of Birth: January 24, 1968

Career summary: September 1990 Various roles in operational and strategic HR functions, Karstadt AG  
 October 2000 Head of HR Development, Thomas Cook  
 May 2003 General Manager Human Resources, Olympus Europa GmbH (currently Olympus Europa SE & Co. KG)

April 2008	Managing Director Corporate Division, Olympus Europa GmbH
November 2011	Executive Managing Director, Olympus Europa SE & Co. KG
September 2013	Managing Director Consumer Business, Olympus Europa SE & Co. KG
April 2017	Corporate Officer, Olympus
April 2019	Chief Administrative Officer, Olympus (present) Supervisory Board (Chairman), Olympus Europa Holding SE (present)
June 2019	Director, Olympus (present) Executive Officer, Olympus (present)
April 2022	Chief Strategy Officer, Olympus (present) ESG Officer, Olympus (present)

Number of shares of the Company held (Of which, the number of shares to be delivered under the stock compensation plan):

75,653  
(73,563)

(2) Newly appointed executive officers  
Frank Drewalowski

Date of Birth:	April 21, 1965	
Career summary:	February 1993	Assistant Product Manager in the International Endoscopy Department, Olympus Europa
	April 2000	Department Manager GI/EUS/BF and Service Marketing Division, Olympus Europa
	April 2006	General Manager Medical Endoscopy & Surgical, Olympus Medical Systems Europa GmbH Managing Director Medical, Olympus Germany
	April 2009	Regional Managing Director Medical, Microscopy and Consumer Business, Olympus Germany
	April 2011	Managing Director Medical Systems Division, Olympus Europa
	April 2019	Executive Managing Director, Olympus Europa
	April 2020	Corporate Officer (present) Global Division Head Endoscopic Solutions Division, Olympus (present)

Number of shares of the  
Company held (Of  
which, the number of  
shares to be delivered  
under the stock  
compensation plan):

14,525  
(14,525)

Gabriela Kaynor

Date of Birth: November 20, 1975

Career summary:

April 2000	Manufacturing Supervisor, Johnson & Johnson Services, Inc.
May 2004	Business Unit Manager, Johnson & Johnson Services, Inc.
February 2007	Engineering Manager, Johnson & Johnson Services, Inc.
July 2008	R&D Director Monitoring & OR Products, SharpSafety, Cardinal Health, Inc. (formerly Covidien plc)
February 2012	Director Program Management Office & Advanced Supplier Development, Cardinal Health, Inc. (formerly Covidien plc)
February 2015	Director of Operations, Acclarent, Inc. (Part of the Johnson & Johnson family of companies)
April 2016	Executive Director Strategy Development & Portfolio Management, Olympus Corporation of the Americas
July 2017	Vice President, Upstream Marketing & PMO, Olympus Corporation of the Americas
April 2019	Senior Vice President, Global Portfolio Management, Strategy & PMO Therapeutic Solutions Division, Olympus
April 2020	Global Division Head Therapeutic Solutions Division, Olympus (present)
April 2022	Corporate Officer, Olympus (present) Board Member, Olympus Corporation of the Americas (present)

Number of shares of the  
Company held (Of  
which, the number of  
shares to be delivered

5,236  
(5,236)

under the stock  
compensation plan):

Shigeto Ohtsuki

Date of Birth:	November 12, 1961	
Career summary:	April 1984	Human Resources, Hitachi, Ltd.
	June 1999	Manager, Human Resources, General Electric Japan, Ltd.
	June 2008	Director & Corporate Officer, Human Resources, Hewlett Packard Japan, Ltd.
	March 2011	Corporate Officer, General Manager of Personnel Department, Shiseido Company, Ltd
	June 2015	Executive Officer, Human Resources and CSR, Miraca Holdings Inc. (currently H.U. Group Holdings, Inc.)
	November 2019	Joined Olympus Corporation
	February 2020	Human Resources Head, Olympus (present)
	April 2020	Corporate Officer, Olympus (present)

Number of shares of the  
Company held (Of  
which, the number of  
shares to be delivered  
under the stock  
compensation plan):

6,543  
(4,633)

Pierre Boisier

Date of Birth:	July 26, 1958	
Career summary:	August 1977	United States Marine Corps
	May 1988	Senior Quality Engineer, Alcon Laboratories, Inc.
	October 1995	General Manager, Gambro Healthcare, Inc.
	April 1999	Vice president of Operations, Coherent, Inc.
	September 2001	Vice President of QA and RA, National Genetics Institute
	February 2004	Director of Quality, EP Technologies, Boston Scientific Corporation
	March 2005	Group Vice President Quality, Cardiovascular, Boston Scientific Corporation
	February 2007	Group Vice President QA Neurovascular, Electrophysiology & Neuromodulation, Boston

		Scientific Corporation
	October 2010	Senior Vice President of Quality, Becton, Dickinson and Company
	April 2015	Executive Vice President and Chief Quality Officer, Becton, Dickinson and Company
	April 2021	Chief Quality Officer, Olympus (present)
	April 2022	Corporate Officer, Olympus (present)

Number of shares of the Company held (Of which, the number of shares to be delivered under the stock compensation plan):

	4,827
	(4,827)

(Note) “Number of shares of the Company held” indicates the number of shares held as of September 30, 2022. It also includes the number of shares each candidate hold through the Officers’ Shareholding Association of the Company, his/her own equity interest held though a company managing stock compensation of the Company as well as the number of shares to be delivered under the stock compensation plan.

- Scheduled date of assuming office  
April 1, 2023